Enfusion, Inc. (NYSE:ENFN) Given Average Recommendation of “Reduce” by Analysts

Enfusion, Inc. (NYSE:ENFN) has received an average recommendation of “Reduce” from the six analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.33.

ENFN has been the topic of several analyst reports. The Goldman Sachs Group lowered shares of Enfusion from a “neutral” rating to a “sell” rating and cut their target price for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th. Bank of America upped their price objective on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. Finally, JPMorgan Chase & Co. lowered Enfusion from a “neutral” rating to an “underweight” rating and reduced their target price for the stock from $11.00 to $9.00 in a report on Tuesday, January 30th.

Institutional Investors Weigh In On Enfusion

Institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in Enfusion during the 4th quarter worth approximately $28,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Enfusion in the first quarter worth $44,000. Amalgamated Bank grew its position in Enfusion by 33.7% in the third quarter. Amalgamated Bank now owns 5,230 shares of the company’s stock valued at $47,000 after purchasing an additional 1,317 shares in the last quarter. UBS Group AG boosted its position in Enfusion by 1,189.8% during the fourth quarter. UBS Group AG now owns 6,204 shares of the company’s stock valued at $60,000 after purchasing an additional 5,723 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of Enfusion by 24.2% during the 1st quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock worth $91,000 after buying an additional 1,390 shares during the period. 81.05% of the stock is owned by institutional investors.

Enfusion Trading Down 2.1 %

NYSE ENFN opened at $9.11 on Friday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 113.83, a PEG ratio of 2.70 and a beta of 1.00. Enfusion has a 1-year low of $7.37 and a 1-year high of $11.56. The company has a 50 day moving average of $9.06 and a 200-day moving average of $9.12.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Tuesday, March 12th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $46.49 million during the quarter, compared to the consensus estimate of $45.56 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. On average, analysts forecast that Enfusion will post 0.07 earnings per share for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.